Edwards Lifesciences CVP Daniel Lippis Executes 10b5-1 Option Exercise and Sale

Executive Summary

On October 8, 2026, Daniel J. Lippis, Corporate Vice President of TAVR at Edwards Lifesciences Corp ($EW), exercised stock options and subsequently sold 619 shares of common stock at a price of $85.65 per share. The gross proceeds from the sale totaled $53,017.35.

Transaction Breakdown

• Option Exercise: Lippis exercised 619 employee stock options with an exercise price of $72.68 per share, which were granted with an expiration date of May 6, 2027.
• Open Market Sale: All 619 acquired shares were disposed of at $85.65 per share under transaction code 'S'.
• 10b5-1 Plan: The exercise and sale were carried out pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 13, 2026.

Post-Transaction Holdings

Following this transaction, Lippis continues to hold 40,033.9103 shares of Edwards Lifesciences common stock directly, alongside 3,095 remaining derivative option contracts from the underlying grant.

Market & Governance Context

Given the relatively small volume (619 shares) and execution via a pre-arranged 10b5-1 plan, this transaction represents standard executive compensation realization rather than a discretionary market timing signal.